Article info

Original research
Gamma delta TCR anti-CD3 bispecific molecules (GABs) as novel immunotherapeutic compounds

Authors

  1. Correspondence to Dr Jürgen Kuball; J.H.E.Kuball{at}umcutrecht.nl
View Full Text

Citation

van Diest E, Hernández López P, Meringa AD, et al
Gamma delta TCR anti-CD3 bispecific molecules (GABs) as novel immunotherapeutic compounds

Publication history

  • Accepted November 2, 2021
  • First published November 23, 2021.
Online issue publication 
November 23, 2021
  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.